Instructions for Authors 2017

General Policy. ANTIcancer Research (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTIcancer RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTIcancer RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/ Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All images should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tif or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**Nomenclature and Abbreviations.** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (http://www.gene.ucl.ac.uk/). Approved mouse nomenclature may be obtained from http://www.informatics.jax.org/. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trial number should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

**Ethical Policies and Standards.** ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

**Specific information and additional instructions for Authors**

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
   • The Instructions to Authors must be followed in every detail.
   • The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
   • The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
   • Results given in figures should not be repeated in tables.
   • Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
   • Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
   • Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
   • Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
   • Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
   • The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
   • By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. Articles submitted to AR may be rejected without review if:
   • they do not fall within the journal's policy.
   • they do not follow the instructions for authors.
   • language is unclear.
   • results are not sufficient to support a final conclusion.
   • results are not objectively based on valid experiments.
   • they repeat results already published by the same or other authors before the submission to AR.
   • plagiarism is detected by plagiarism screening services.
   (Rejection rate (2016): 66%).

10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2017 - International Institute of Anticancer Research (G.J. Delineasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal’s scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the International Institute of Anticancer Research (IIAR) and is available online with Stanford University HighWire Press. The IIAR is a member of UICC. For more information please visit our website www.cgp.iiarjournals.org.

The Multiple Roles of Exosomes in Metastasis. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGEN, R. RÜGER (Basel, Switzerland)

Phosho-Network Analysis Identifies and Quantifies Hepatitis C Virus (HCV)-induced Hepatocellular Carcinoma (HCC) Proteins Regulating Viral Mediated Tumor Growth. N.T. LU, N.M. LIU, J.Q. VU, D. PATEL, W. COHN, J. CAPRI, M. ZIEGLER, N. PATEL, A. TRAMONTANO, R. WILLIAMS, J. COX, J. WHITELEGGE, S.W. FRENCH (Los Angeles, CA; Boston, MA, USA; London, UK)

The Selection of Recent Articles

Differential Expression of Wisp1 (Ccn4) and Other Genes Between Metastatic and Non-metastatic EL4 Mouse Lymphoma Cells. M.S. CHAHAL, H.T. KU, Z. ZHANG, C.M. LEGASPI, A. LUO, M.M. HOPKINS, K.E. MEIER (Spokane, WA; Duarte, CA, USA)

Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. M. MEDINGER, C. LENGERKE, J. PASSWEG (Basel, Switzerland)


Phospho-Network Analysis Identifies and Quantifies Hepatitis C Virus (HCV)-induced Hepatocellular Carcinoma (HCC) Proteins Regulating Viral Mediated Tumor Growth. N.T. LU, N.M. LIU, J.Q. VU, D. PATEL, W. COHN, J. CAPRI, M. ZIEGLER, N. PATEL, A. TRAMONTANO, R. WILLIAMS, J. COX, J. WHITELEGGE, S.W. FRENCH (Los Angeles, CA; Boston, MA, USA; London, UK)
General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.

The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.
U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.
E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles


Wound Healing is Delayed in the ZDSD Rat. M.A. SUCKOW, T.A. GOBBETT, R.G. PETERSON (St. Paul, MN; Indianapolis, IN, USA)

Active and Passive Immunization Against Staphylococcus aureus Periprosthetic Osteomyelitis in Rats. N.H. SOE, N.V. JENSEN, A.L. JENSEN, J. KOCH, S.S. POULSEN, G.B. PIER, H.K. JOHANSEN (Copenhagen; Ballerup; Hørsholm, Denmark; Boston, MA, USA)


A Model of the Development of Cisplatin Resistance in Human Small Cell Lung Cancer Xenografts. P.B. CAFFREY, G.D. FRENKEL, K.L. MCANDREW, K. MARKS (California; Pittsburgh, PA; Newark, NJ, USA)

Applicability of Commercially Available ELISA Kits for the Quantification of Faecal Immuno-reactive Corticosterone Metabolites in Mice. K.S.P. ABELSON, O. KALLIOKOSKI, A.C. TEILMANN, J. HAU (Copenhagen, Denmark)

Gene Expression Analysis of Cultured Rat-Endothelial Cells after Nd: YAG Laser Irradiation by Affymetrix GeneChip Array. Y. MASUDA, S. YOKONES, H. SAKAGAMI (Saitama, Japan)


Induction of TGF-β by Irradiation or Chemotherapy in Fanconi Anemia (FA) Mouse Bone Marrow is Modulated by Small Molecule Radiation Mitigators JP4-039 and MMS350. M.W. EPPERLY, D. FRANICOLA, T. DIXON, S. CAO, X. ZHANG, D. SHIELDS, H. WANG, P. WIPF, J.S. GREENBERGER (Pittsburgh, PA, USA)

Prognostic Impact of a Nutritional Index Including Muscle Volume in Stage 4 Colorectal Cancer. T. NAGATA, Y. NAKASE, K. NAKAMURA, A. SOUGAWA, S. MOCHIDUKI, S. KITAI, S. INABA (Nara, Japan)

Cell Pleomorphism and Cytoskeleton Disorganization in Human Liver Cancer. C.-C. CHENG, Y.-C. LAI, Y.-S. LAI, W.-T. CHAO, Y.-H. TSENG, Y.-H. HSU, Y.-Y. CHEN, Y.-H. LIU (Changhua; Taichung; Kaohsiung; Hualien, Taiwan, ROC)

The Effect of Induced Antibodies with Respect to Neutralization, Clearance Rate and Functional Activity in a Rabbit/Infliximab Model. M.L. HENRIKSEN, A. TEISNER, J. KJELDSEN, O. KALLIOKOSKI, J. HAU, S. WERNER, K. HANSEN (Odense; Copenhagen, Denmark)

Palliative Radiotherapy in Cancer Patients with Increased Serum C-reactive Protein Level. C. NIEDER, B. MANNSÅKER, A. DALHAUG, A. PAWINSKI, E. HAUKLAND (Tromso; Bodø, Norway)

Simvastatin Inhibits Epithelial-to-Mesenchymal Transition Induction of HO-1 in Cultured Renal Proximal Tubule Cells. J.S. CLARK, A.J. CARTER, M. DIXIT, I. ARANY (Jackson, MS, USA)

Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients. M. STOTZ, S.A. HERZOG, M. PICHLER, M. SMOLLE, J. RIEDL, C. ROSSMANN, A. BEZAN, H. STÖGER, W. RENNER, A. BERGHOFT, A. GERGER (Graz, Austria) ................................................................................ 2011


Comprehensive Surgical Treatment as the Mainstay of Management in Retroperitoneal Sarcomas: Retrospective Study from Two Non-sarcoma Specialist Centers. A. PETROU, A. CONSTANTINIDOU, M. KONTOS, A. PAPALAMPROS, D. MORIS, C. BAKOYIANNIS, K. NEOFYTOU, G. KOUROUNIS, E. FELEKOURAS (Nicosia, Cyprus; London, UK; Athens, Greece) .................................................................................................................................................................................. 2025

Second Primary Malignancy in Bladder Carcinoma – A Population-based Study. A. KHANAL, N. BUDHATHOKI, V.P. SINGH, B.K. SHAH (Chicago, IL; Brooklyn, NY; Sedro-Woolley, WA, USA; Osbourn, Antigua) ........................................................................................................................................................................... 2033


Salvage Robotic-assisted Laparoscopic Radical Prostatectomy: Experience with 14 Cases. Y.-C. OU, S.-C. HUNG, L.-H. HWANG, C.-K. YANG, S.-W. HUNG, M.-C. TUNG (Taichung; Taipei, Taiwan, ROC) ................................................................................................................................................................................... 2045


Expression of Anti-apoptotic Protein BAG3 in Human Sebaceous Gland Carcinoma of the Eyelid. T. YUNOKI, Y. TABUCHI, A. HAYASHI (Toyama, Japan)

Unstaged Diffuse Large B-Cell Lymphoma in the United States: Predictors and Patient Outcomes. A. BISTA, S. SHARMA, T. RIJWANI, B.K. SHAH (Sayre, PA; Yakima, WA; Sedro-Woolley, WA, USA)

Effects of Lidocaine on HT-29 and SW480 Colon Cancer Cells In Vitro. A.C. BUNDSCHERER, M. MALSY, D.I. BITZINGER, C.H.R. WIESE, M.A. GRUBER, B.M. GRAF (Regensburg; Braunschweig, Germany)


A Retrospective Analysis of Ki-67 Index and its Prognostic Significance in Over 800 Primary Breast Cancer Cases. F. THANGARAJAH, J. ENNINGA, W. MALTER, S. HAMACHER, B. MARKIEFLA, L. RICHTERS, S. KRÄMER, P. MALLMANN, V. KIRN (Cologne; Krefeld, Germany)


Analysis of Factors Affecting Short-term Results in Elderly Patients Undergoing Elective Surgical Resection for Stage I-II Colon Cancer. S.M.M. BASSO, F. LUMACHI, P. PIANON, G. FANTI, F. MAFFEIS, P. UBIALI (Padua, Italy)


Continuation of a Levonorgestrel Intrauterine Device During Hematopoietic Stem Cell Transplant: A Case Report. P.C. BRADY, R.J. SOIFFER, E.S. GINSBURG (Boston, MA, U.S.A.)

Prognostic Value of "Prepectoral Edema" in MR-mammography. C.G. KAISER, M. HEROLD, J. KRAMMER, P. BALTZER, M. GAIDA, O. CAMARA, S. SCHÖNBERG, W.A. KAISER, M. DIETZEL (Mannheim; Jena; Erlangen, Germany; Vienna, Austria)

Clinical Studies

Neurovascular Bundle Infiltration Can Explain Local Relapses Using Conformal Radiotherapy of Prostate Cancer. A.K. JOHANSSON, B. LENNERNÄS, U. ISACSSON (Uppsala; Eskilstuna; Örebro, Sweden)..............


Ovarian Cancer Surgery – A Population-based Registry Study. P. LEANDERSSON, G. GRANÅSEN, C. BORGFEHLDT (Lund; Umeå, Sweden).................................................................

Human Papilloma Virus-positive Oropharyngeal Squamous Cell Carcinoma in the Elderly. E. DAVE, W. SU, V. GUPTA, B. MILES, E. DEMICCO, T. SORIANO, R.L. BAKST (New York, NY, USA) ..............................................

Type-2 Diabetes Mellitus and Oral Tumors in Hungary: A Long-term Comparative Epidemiological Study. D. VÉGH, D. BÁNYAI, P. HERMANN, Z. NÉMETH, M. UJPÁL (Budapest, Hungary)........................................

Chemoembolization with Drug-eluting Microspheres Loaded with Doxorubicin for the Treatment of Cholangiocarcinoma. C. ALIBERTI, R. CARANDINA, D. SARTI, E. PIZZIRANI, G. RAMONDO, L. MULAZZANI, G.M. MATTIOLI, G. FIORENTINI (Pesaro; Padua, Italy).................................................................

Linear Stapling Device with Pre-attached Bioabsorbable Polyglycolic Acid Felt Reduces Postoperative Pancreatic Fistula After Distal Pancreatectomy. Y.-I. YAMASHITA, E. TSUJITA, A. CHIKAMOTO, K. IMAI, T. KAIDA, T. YAMAO, N. UMEZAKI, S. NAKAGAWA, D. HASHIMOTO, H. BABA (Kumamoto; Fukuoka, Japan)........

A Retrospective Evaluation of Bevacizumab Treatment in Patients with Progressive Malignant Glioma in Northern Sweden. M. SANDSTRÖM, M. LAUDIUS, T. LINDQVIST, T. ASKLUND, M. JOHANSSON (Umeå, Sweden)..............................................................................................................

Comparison of Efficacy of Adjuvant MEC (Methotrexate, Epirubicin and Cisplatin) and GC (Gemcitabine and Cisplatin) in Advanced Upper Tract Urothelial Carcinoma. S.-C. HUNG, S.-S. WANG, C.-K. YANG, J.-R. LI, C.-L. CHENG, Y.-C. OU, H.-C. HO, K.-Y. CHIU, C.-S. CHEN (Taipei; Puli, Taiwan, ROC).................................................................

Retrospective Investigation of Cutaneous Squamous Cell Carcinoma on the Lip Treated with Peplomycin Administered Through a Superficial Temporal Artery. T. FUJIMURA, K. TAKAHASHI, Y. KAMBAYASHI, S. FURUDATE, T. HIDAKA, A. KAKIZAKI, A. WATABE, T. HAGA, A. HASHIMOTO, S. AIBA (Sendai; Morioka, Japan)......................................................................................

High HMG A2 Expression Correlates with Reduced Recurrence-free Survival and Poor Overall Survival in Oral Squamous Cell Carcinoma. C.-Y. FANG, P.-L. LIEW, C.-L. CHEN, Y.-H. LIN, C.-L. FANG, W.-Y. CHEN (Taipei; New Taipei City, Taiwan, ROC).................................................................


Preoperative Pancreatic Stiffness by Real-time Tissue Elastography to Predict Pancreatic Fistula After Pancreaticoduodenectomy. N. HARADA, T. YOSHIZUMI, T. MAEDA, H. KAYASHIMA, T. IKEGAMI, N. HARIMOTO, S. ITOH, Y. MAEHARA (Fukuoka; Hiroshima, Japan).................................................................

A Locally Advanced Breast Cancer that Achieved pCR with Pertuzumab, Trastuzumab and Docetaxel: Case Report. Y. INOUE, N. YAMASHITA, E. TOKUNAGA, K. TANAKA, H. UEO, H. SAEK I, E. OKI, H. YAMAMOTO, Y. MAEHARA (Fukuoka, Japan)......................................................................................
Photodynamic Therapy Mediated by a Novel Chlorin Derivative, TONS 501-Na, in EMT6 cells. T. OSAKI, I. SAKA-Ta, Y. UTO, K. AZUMA, Y. MURAHATA, T. TSUKA, N. ITOH, T. IMAGAWA, Y. OKAMOTO (Tottori; Okayama; Tokushima, Japan) .......................................................................................................................... 1723

Clinical Significance of DNA Damage Response Factors and Chromosomal Instability in Primary Lung Adenocarcinoma. T. OKAMOTO, M. KOHNO, K. ITO, K. TAKADA, M. KATSURA, Y. MORODOMI, G. TOYOKAWA, F. SHOJI, Y. MAEHARA (Fukuoka, Japan) .................................................................................................................. 1729

Synergistic Effect of Carboplatin and Piroxicam on Two Bladder Cancer Cell Lines. J. SILVA, R. ARANTES-RODRIGUES, R. PINTO-LEITE, A.I. FAUSTINO-ROCHA, L. FIDALGO-GONÇALVES, L. SANTOS, P.A. OLIVEIRA (Vila Real; Porto; Lisbon, Portugal) ................................................................................................................. 1737

Salinomycin Induces Reactive Oxygen Species and Apoptosis in Aggressive Breast Cancer Cells as Mediated with Regulation of Autophagy. K.-Y. KIM, K.I. PARK, S.-H. KIM, S.-N. YU, D. LEE, Y.W. KIM, K.T. NOH, J.Y. MA, Y.-K. SEO, S.-C. AHN (Gyeongsan; Daegu; Yangsan; Ulsan; Daejeon, Republic of Korea) ............ 1747

Liposomes Incorporating Transferrin and Stearic Acid-modified Octa-arginine for siRNA Delivery. D. YANG, X. YANG, R.J. LEE, S. LIU, J. XIE (Changchun; Zuhuai, PR China; Columbus, OH, USA) ........................................................................................................................................................................ 1759

Characterization of Leiomyomatoid Angiomatous Neuroendocrine Tumour (LANT)-like Tumour in the Myometrium with Histopathological Examination. T. HAYASHI, T. ICHIMURA, M. KASAI, K. SANO, D. ZHARHARY, T. SHIOZAWA, N. YAEGASHI, I. KONISHI (Nagano; Osaka; Nagano; Miyagi; Kyoto, Japan; Rehovot, Israel) .................................................................................................................................................... 1765


Expression of RNA-binding Motif Protein 3 (RBM3) and Cold-inducible RNA-binding protein (CIRP) Is Associated with Improved Clinical Outcome in Patients with Colon Cancer. H.H. JANG, H.N. LEE, S.-Y. KIM, S. HONG, W.-S. LEE (Incheon, Republic of Korea) ........................................................................................................................................ 1779


Dynamic Phenotypic Transition of Breast Cancer Cells In Vitro Revealed by Self-floating Cell Culture. Y. OKU, N. NISHIYA, K. TSUDA, MASAKIHO SHIBAZAKI, C. MAESAWA, Y. UEHARA (Iwate, Japan) ........................................................................................................................................................................ 1793

bFGF Polymorphism Is Associated with Disease Progression and Response to Chemotherapy in Multiple Myeloma Patients. T. WRÓBEL, A. BUTRYM, P. ŁACINA, J. RYBKA, K. GĘBURA, G. MAZUR, K. BÖGUNIA-KUBIK (Wroclaw, Poland) ......................................................................................................................................................... 1799

PI3K Catalytic Isoform Alteration Promotes the LIMK1-related Metastasis Through the PAK1 or ROCK1/2 Activation in Cigarette Smoke-exposed Ovarian Cancer Cells. G.B. PARK, D. KIM (Busan, Republic of Korea) .................................................................................................................................................................................. 1805


Contents continued on the preceding page
Antitumor Activities of the Novel Isosteviol Derivative 10C Against Liver Cancer. A. MALKI, A. EL-
SHARKAWY, M. EL SYAED, S. BERGMEIER (Doha, Qatar; Alexandria, Egypt; Athens, OH, USA) ............

Y-box Binding Protein 1 Is Involved in Regulating the G2/M Phase of the Cell Cycle. Y. KOTAKE, N.
ARIKAWA, K. TAHARA, H. MARU, M. NAEMURA (Fukuoka, Japan) .................................................................

Self-efficacy for Coping Moderates the Effects of Distress on Quality of Life in Palliative Cancer Care. A.
CHIRICO, S. SERPENTINI, T. MERLUZZI, L. MALLIA, P. DEL BIANCO, R. MARTINO, L. TRENITIN, E.
BUCCI, M. DE LAURENTISIIS, E. CAPOVILLA, F. LUCIDI, G. BOTTI, A. GIORDANO (Rome; Padua;
Bassano del Grappa; Naples; Siena, Italy; Notre Dame, IN; Philadelphia, PA, USA) ...........................................

CURLEY JR, N. FATIMA, S. AHMED, L.C. CHANG, E.J. CARCACHE DE BLANCO (Columbus, OH; Hilo,
HI, USA; Islamabad, Pakistan) ....................................................................................................................................

New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines. A.
KLEJEWSKI, M. ŚWIERCZEWSKA, K. ZAORSKA, M. BRĄZERT, M. NOWICKI, M. ZABEL, R.
JANUCHOWSKI (Poznan, Poland) ............................................................................................................................

Methylsulfonylmethane Induces G1 Arrest and Mitochondrial Apoptosis in YD-38 Gingival Cancer Cells. N.
Busan, Republic of Korea) ............................................................................................................................................

ME-143 Is Superior to Genistein in Suppression of WNT Signaling in Colon Cancer Cells. S. PINTOVA, K.
PLANUTIS, M. PLANUTIENE, R.F. HOLCOMBE (New York, NY, USA) ............................................................

Actinomycin D Down-regulates SOX2 Expression and Induces Death in Breast Cancer Stem Cells. T. DAS,
(Tampa, FL, USA) ..........................................................................................................................................................

Systematic Trial for Evaluating Docetaxel in a Human Prostate Cancer Cell DU145 Xenograft Model. M.
MABUCHI, M. UEDA, Y. YOSHIDA, K. HORIIKE, K. YAMAOKA, S. NAKAO, T. SHIMIZU, Y. UEDA,
K, TSUJIKAWA, A. TANAKA (Kobe; Suita, Japan) ................................................................................................

Effect of Whole-abdominal Irradiation on Penetration Depth of Doxorubicin in Normal Tissue After Pressurized
Intraperitoneal Aerosol Chemotherapy (PIPAC) in a Post-mortem Swine Model. V. KHOSRAWIPOUR, T.
KHOSRAWIPOUR, Y. HEDAYAT-POUR, D. DIAZ-CARBALLO, A. BELLENDORF, H. BÖSE-RIEIRO,
R. MUCKE, N. MOHANARAJA, I.A. ADAMIEKTZ, K. FAKHRIAN (Bochum; Essen, Germany).......................... 1677

DNA Double-strand Breaks Induced by Fractionated Neutron Beam Irradiation for Boron Neutron Capture
Therapy. Y. KINASHI, N. YOKOMIZO, S. TAKAHASHI (Kumatori, Japan) ................................................................. 1681

Ninjurin1 Is Up-regulated in Circulating Prostate Tumor Cells and Plays a Critical Role in Prostate Cancer Cell
Motility. J. PARK, J.-Y. JOUNG, J.-E. HWANG, D. HONG, W.S. PARK, S.-J. LEE, K.H. LEE (Goyang,
Republic of Korea) .................................................................................................................................................... 1687

Caspase-6 Induces 7A6 Antigen Localization to Mitochondria During FAS-induced Apoptosis of Jurkat Cells.
H. SUITA, T. SHINOMIYA, Y. NAGAHARA (Hatoyama, Japan) ................................................................................ 1687

Myricetin Induces Apoptosis of Human Anaplastic Thyroid Cancer Cells via Mitochondria Dysfunction. S. JO,
of Korea) .................................................................................................................................................................. 1705

Bisphenol A Inhibits Cell Proliferation and Reduces the Motile Potential of Murine LM8 Osteosarcoma Cells.
T. KIDANI, R. YASUDA, J. MIYAWAKI, Y. OSHIMA, H. MIURA, H. MASUNO (Toon; Tobe, Japan) ........... 1711